Broken out by business line, RTI Biologics saw a 7 percent revenue increase for sports medicine ($11.8 million), a 5 percent revenue increase for surgical specialties ($7.9 million) and a 13 percent revenue increase for bone graft substitutes and general orthopedics ($7.9 million).
More Articles on Orthopedic Devices:
New Instrumentation & Partnership for DePuy Synthes Spine
DePuy Synthes Spine Launches Minimally Invasive Posterior-Lateral Fusion System
